Table 2. Clinical details of patients included in the study.
| No. | Age at diagnosis of OC (years) | Sex | Other cancer history | Chemo therapy | Chemotherapy agent | Radiotherapy | G-CSF application | BRCA (1/2) mutation | Best response of a PARPi | Duration of PARPi medication (months) | Time between PARPi initiation and diagnosis of t-MNs (months) | Time between PARPi termination and diagnosis of t-MNs (months) | Time between OC and diagnosis of t-MNs (years) | OC status at t-MNs | Survival status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 42 | F | Breast cancer (NED) | Yes | Paclitaxel; carboplatin; topotecan; cisplatin; docetaxel; ifosfamide; gemcitabine; cyclophosphamide | Yes | Yes | BRCA 1 | PR | 16.7 | 59.9 | 43.2 | 15.1 | Stage IV | No |
| 2 | 47 | F | – | Yes | Paclitaxel; carboplatin; bevacizumab; topotecan; pegylated liposomal doxorubicin | Yes | Yes | BRCA 1 | NED maintenance | 48.8 | 59.9 | 11.1 | 17.5 | Stage IV | No |
| 3 | 43 | F | – | Yes | Paclitaxel; carboplatin; pegylated liposomal doxorubicin; topotecan; navelbine; cisplatin pembrolizumab | Yes | Yes | BRCA 1 | PR | 6.2 | 24.6 | 18.4 | 11.7 | Stage IV | No |
| 4 | 53 | F | Breast cancer (NED) | Yes | Paclitaxel; carboplatin; bevacizumab; pegylated liposomal doxorubicin; docetaxel; topotecan; pembrolizumab | Yes | Yes | BRCA 1 | NED maintenance | 15.9 | 54.1 | 38.2 | 8.2 | NED | Yes |
OC, ovarian cancer; G-CSF, granulocyte colony-stimulating factor; BRCA, breast cancer gene; PARPi, poly(ADP-ribose) polymerase inhibitor; t-MNs, therapy-related myeloid neoplasms; F, female; NED, no evidence of disease; PR, partial response.